Vantage logo

GSK’s tribulations continue

Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.

Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.